A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.
Public ClinicalTrials.gov record NCT00141934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to establish its efficacy and safety, AD 452 is being tested in a 3 month study. Patients enrolled in this study will already be taking methotrexate for their RA and they will remain on methotrexate throughout the study. An earlier clinical study in 98 subjects with RA on stable background therapy investigated the pharmacokinetics, safety and tolerability of AD 452 taken for one month. The drug was well tolerated and no significant drug related adverse events were reported.
Study identification
- NCT ID
- NCT00141934
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 232 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2005
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Apr 4, 2007
Started 2005
United States locations
- U.S. sites
- 10
- U.S. states
- 4
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research of West Florida, Inc | Clearwater | Florida | 33765 | — |
| Center for Rheumatology, Immunology and Arthritis | Fort Lauderdale | Florida | 33334 | — |
| Ocala Rheumatology Research Center | Ocala | Florida | 34474 | — |
| Sarasota Arthritis Research Center | Sarasota | Florida | 34239 | — |
| Advent Clinical Research Centers, Inc. | St. Petersburg | Florida | 33703 | — |
| Dept of Rheumatology, Columbia Medical Practice | Columbia | Maryland | 21045 | — |
| Anderson and Collins Clinical Research, Inc. | Edison | New Jersey | 08817 | — |
| Station Avenue | Haddon Heights | New Jersey | 08035 | — |
| Atlantic Coast Research LLC | Toms River | New Jersey | 08755 | — |
| Rheumatic Disease Associates | Willow Grove | Pennsylvania | 19090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00141934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2007 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00141934 live on ClinicalTrials.gov.